Woodline Partners’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-306,946
| Closed | -$253K | – | 993 |
|
|
2025
Q1 | $253K | Sell |
306,946
-2,651
| -0.9% | -$2.55K | ﹤0.01% | 868 |
|
|
2024
Q4 | $294K | Hold |
309,597
| – | – | ﹤0.01% | 890 |
|
|
2024
Q3 | $310K | Buy |
+309,597
| New | +$343K | ﹤0.01% | 556 |
|
|
2023
Q4 | – | Sell |
-173,877
| Closed | -$226K | – | 572 |
|
|
2023
Q3 | $226K | Hold |
173,877
| – | – | ﹤0.01% | 546 |
|
|
2023
Q2 | $299K | Hold |
173,877
| – | – | ﹤0.01% | 575 |
|
|
2023
Q1 | $254K | Buy |
173,877
+94,742
| +120% | +$182K | ﹤0.01% | 577 |
|
|
2022
Q4 | $128K | Sell |
79,135
-8,799
| -10% | -$20.3K | ﹤0.01% | 705 |
|
|
2022
Q3 | $295K | Sell |
87,934
-251,439
| -74% | -$1.13M | ﹤0.01% | 621 |
|
|
2022
Q2 | $1.24M | Buy |
339,373
+148,342
| +78% | +$672K | 0.02% | 494 |
|
|
2022
Q1 | $1.38M | Sell |
191,031
-118,566
| -38% | -$1.01M | 0.02% | 445 |
|
|
2021
Q4 | $4.21M | Sell |
309,597
-191,031
| -38% | -$2.99M | 0.06% | 308 |
|
|
2021
Q3 | $10.5M | Hold |
500,628
| – | – | 0.17% | 157 |
|
|
2021
Q2 | $12M | Buy |
500,628
+312,543
| +166% | +$7.91M | 0.22% | 115 |
|
|
2021
Q1 | $5.5M | Sell |
188,085
-33,402
| -15% | -$978K | 0.12% | 181 |
|
|
2020
Q4 | $6.62M | Buy |
+221,487
| New | +$6.95M | 0.18% | 143 |
|
Woodline Partners's KRON Position: Q2 2025 in Review
Woodline Partners sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 306,946 shares — an estimated $253K sold.
Woodline Partners first reported a position in KRON in Q4 2020 and held it in 15 quarters. The position peaked at $12M in Q2 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Woodline Partners reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Woodline Partners sold 306,946 Kronos Bio shares in Q2 2025, an estimated $253K.
- Woodline Partners first reported a position in Kronos Bio in Q4 2020 and held it in 15 quarters.
- Woodline Partners's Kronos Bio position peaked at $12M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.